Division of Cardiology, Department of Medicine, Karolinska Institute, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
AstraZeneca, Gothenburg, Sweden.
Eur J Heart Fail. 2021 Sep;23(9):1499-1511. doi: 10.1002/ejhf.2271. Epub 2021 Jun 28.
Use and dosing of guideline-directed medical therapy (GDMT) in patients with heart failure (HF) have been shown to be suboptimal. Among new users of GDMT in HF, we followed the real-life patterns of dose titration and discontinuation of angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-blockers, mineralocorticoid receptor antagonists (MRA) and angiotensin receptor-neprilysin inhibitors (ARNI).
New users were identified in health care databases in Sweden, UK and US between 2016-2019. Inclusion criterion was a recent HF hospitalization (HHF) triggering the initiation of GDMT. Patients were grouped by GDMT, i.e. ACEi, ARB, beta-blocker, MRA and ARNI, and stratified by initial dose. Follow-up was 12 months, until death or study end. Outcomes were dose titration within each drug class, discontinuation and first HHF or death. Dose/discontinuation follow-up was assessed daily based on the coverage length of a filled prescription and reported on day 365. New users of ACEi (n = 8426), ARB (n = 2303), beta-blockers (n = 10 476), MRA (n = 17 421), and ARNI (n = 29 546) were identified. Over 12 months, target dose achievement was 15%, 10%, 12%, 30%, and discontinuation was 55%, 33%, 24% and 27% for ACEi, ARB, beta-blockers and ARNI, respectively. MRA was rarely titrated and discontinuation rates were high (40%). Event rates for HHF or death ranged from 40.0-86.9 per 100 patient-years across the treatment groups.
Despite high risk of clinical events following HHF, new initiation of GDMT was followed by consistent patterns of low up-titration and early GDMT discontinuation in three countries with different health care and economies. Our data highlight the urgent need for moving away from long sequential approach when initiating HF treatment and for improving just-in-time decision support for patients and health care providers.
已证实,心力衰竭(HF)患者指南指导的医学治疗(GDMT)的使用和剂量并不理想。在 HF 中 GDMT 的新使用者中,我们遵循了血管紧张素转换酶抑制剂(ACEi)、血管紧张素受体阻滞剂(ARB)、β受体阻滞剂、盐皮质激素受体拮抗剂(MRA)和血管紧张素受体脑啡肽酶抑制剂(ARNI)的剂量滴定和停药的真实模式。
在瑞典、英国和美国的医疗保健数据库中,于 2016-2019 年期间确定了新使用者。入选标准为最近因 HF 住院(HHF)而启动 GDMT。患者按 GDMT 分组,即 ACEi、ARB、β受体阻滞剂、MRA 和 ARNI,并按初始剂量分层。随访 12 个月,直至死亡或研究结束。结局是每个药物类别内的剂量滴定、停药以及首次 HHF 或死亡。根据处方的覆盖长度,每天评估剂量/停药随访,并在第 365 天报告。确定了 ACEi(n=8426)、ARB(n=2303)、β受体阻滞剂(n=10476)、MRA(n=17421)和 ARNI(n=29546)的新使用者。在 12 个月内,目标剂量达标率分别为 ACEi 15%、ARB 10%、β受体阻滞剂 12%、ARNI 30%和 ACEi 55%、ARB 33%、β受体阻滞剂 24%、ARNI 27%。MRA 很少进行滴定,停药率较高(40%)。HHF 或死亡的事件发生率在治疗组中为 40.0-86.9/100 患者年。
尽管 HHF 后临床事件的风险较高,但在具有不同医疗保健和经济体系的三个国家,GDMT 的新启动后,剂量递增一致且早期停药。我们的数据突出表明,迫切需要从 HF 治疗的启动开始,采用即时决策支持,避免长期连续方法,并为患者和医疗保健提供者提供即时决策支持。